NCT00496561

Effect of Specific Immunotherapy to Dust Mites in Children With Asthma

Evaluation of Early Clinical and Immunological Efficacy of Specific Immunotherapy to Dust Mites in Children With Asthma

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Medical University of Lodz · Academic / Other
• Sex: All
• Age: 6 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SIT in children with asthma.

Detailed description

Specific immunotherapy is the only one causal treatment method of atopic diseases including bronchial asthma in children. The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms,reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SIT in children with asthma.

Conditions

• Asthma

Interventions

Type	Name	Description
BIOLOGICAL	subcutaneous immunotherapy (House Dust Mites)	subcutaneous immunotherapy (House Dust Mites)
OTHER	placebo of subcutaneous immunotherapy (House Dust Mites)	placebo of subcutaneous immunotherapy (House Dust Mites)

Timeline

• Start date: 2006-08-01
• Primary completion: 2013-11-01
• Completion: 2013-12-01
• First posted: 2007-07-04
• Last updated: 2013-02-07

Locations

1 site across 1 country: Poland